抗人 ID2 抗体对
01AB01969
Inhibitor of DNA binding 2 (ID2) is a nuclear transcriptional regulator of the ID family characterized by a helix-loop-helix (HLH) dimerization domain. Lacking a basic DNA-binding region, ID2 cannot bind DNA directly; instead, it functions as a dominant-negative inhibitor by forming heterodimers with basic HLH (bHLH) transcription factors. This interaction prevents bHLH factors from binding to their target DNA sequences, thereby modulating critical cellular processes including growth, senescence, differentiation, and apoptosis. ID2 plays a pivotal role in lineage commitment, negatively regulating skeletal and cardiac muscle differentiation while restraining lymphoid development. Clinically, dysregulated ID2 expression is implicated in tumor biology, particularly in the development and therapy resistance of glioblastoma and Ewing sarcoma. By controlling proliferation and differentiation, ID2 contributes to oncogenesis and represents a context-dependent therapeutic target in various malignancies.
| 规格 | 起售价 |
|---|---|
| 登录后可查看 | |
技术参数
- 靶点基因名
- ID2
- 基因别名
- BHLHB26
- 蛋白别名
- inhibitor of DNA binding 2; ID2
- UniProt
- Q02363
- 物种
- Human
产品详情
- 靶点名称
- ID2
- 蛋白名称
- inhibitor of DNA binding 2
- 蛋白别名
- DNA-binding protein inhibitor ID-2; Class B basic helix-loop-helix protein 26; bHLHb26; Inhibitor of DNA binding 2; Inhibitor of differentiation 2
- 靶点基因名
- ID2
- 基因别名
- BHLHB26
- UniProt
- Q02363
- 来源物种
- Homo sapiens (Human)
- 物种反应性
- Human
背景介绍
Inhibitor of DNA binding 2 (ID2) is a nuclear transcriptional regulator of the ID family characterized by a helix-loop-helix (HLH) dimerization domain. Lacking a basic DNA-binding region, ID2 cannot bind DNA directly; instead, it functions as a dominant-negative inhibitor by forming heterodimers with basic HLH (bHLH) transcription factors. This interaction prevents bHLH factors from binding to their target DNA sequences, thereby modulating critical cellular processes including growth, senescence, differentiation, and apoptosis. ID2 plays a pivotal role in lineage commitment, negatively regulating skeletal and cardiac muscle differentiation while restraining lymphoid development. Clinically, dysregulated ID2 expression is implicated in tumor biology, particularly in the development and therapy resistance of glioblastoma and Ewing sarcoma. By controlling proliferation and differentiation, ID2 contributes to oncogenesis and represents a context-dependent therapeutic target in various malignancies.